Nordic Randomized Trial on Laparoscopic Versus Vaginal Cerclage
NORACT
2 other identifiers
interventional
188
1 country
2
Brief Summary
Every year 15 million babies are born prematurely, which can lead to death or life-long disabilities. It is often caused by a dysfunction of the uterine cervix, which constitutes the narrow channel between the vagina and womb. During pregnancy, this channel must remain closed until the beginning of term labor. A weak cervix may not withstand the weight of the fetus, the amniotic fluid and the placenta and the cervical canal will open and cause late miscarriage or preterm delivery. To prevent this, a band (cerclage) can be applied around the cervix either vaginally or laparoscopically prior to a new pregnancy. To evaluate which treatment is best for most women, we will randomize (allocate by chance) women at risk for preterm birth, to either vaginal cerclage or laparoscopic cerclage in the Nordic countries and England
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2024
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2023
CompletedFirst Posted
Study publicly available on registry
November 8, 2023
CompletedStudy Start
First participant enrolled
January 31, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
December 10, 2024
September 1, 2024
3.8 years
November 3, 2023
December 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Delivery <32+0 weeks of gestation.
In the first subsequent viable pregnancy beyond 14+0 weeks of gestation. First prioritized primary outcome.
At birth.
Baby death.
Loss of a viable pregnancy beyond 14+0 weeks of gestation, miscarriage, stillbirth or death of a live born infant. Second prioritized primary outcome.
From birth - four weeks after due date. In the first subsequent viable pregnancy beyond 14 weeks of gestation.
Secondary Outcomes (32)
Maternal mortality - surgery related.
30 days after insertion of laparoscopic or vaginal cerclage.
Maternal mortality.
From time of randomisation - 42 days after delivery.
Maternal morbidity - surgery related.
30 days after insertion of laparoscopic or vaginal cerclage.
Maternal morbidity
From time of randomisation - 42 days after delivery.
Harm to participant - surgery related.
30 days after insertion of laparoscopic or vaginal cerclage.
- +27 more secondary outcomes
Study Arms (2)
Intervention
EXPERIMENTALLaparoscopic cerclage
Control
EXPERIMENTALVaginal cerclage
Interventions
Classic or robot-assisted laparoscopic cerclage in non-pregnant or early pregnant women.
Eligibility Criteria
You may qualify if:
- Women in whom the clinician has equipoise as to whether an elective vaginal or abdominal cerclage will be the best intervention to prevent preterm birth.
- Not yet pregnant or \<10 weeks' pregnant.
You may not qualify if:
- Any condition or circumstance under which laparoscopic or vaginal cerclage surgery is contraindicated (i.e. on-going pregnancy of more than 10+0 gestational weeks).
- Language difficulties.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Aarhuslead
- Rigshospitalet, Denmarkcollaborator
- Viborg Regional Hospitalcollaborator
- Gødstrup Hospitalcollaborator
- Aalborg University Hospitalcollaborator
- Randers Regional Hospitalcollaborator
- Regionshospital Nordjyllandcollaborator
- Odense University Hospitalcollaborator
- Hvidovre University Hospitalcollaborator
- Oslo University Hospitalcollaborator
- Herlev Hospitalcollaborator
- Aarhus University Hospitalcollaborator
- Horsens Hospitalcollaborator
- Bornholm Hospital, Denmarkcollaborator
- Lund University Hospitalcollaborator
Study Sites (2)
Aarhus University Hospital
Aarhus N, Denmark
Rigshospitalet
Copenhagen, Denmark
Related Publications (1)
Hansen LK, Krogh LQ, Lantto A, Uldbjerg N, Jensen PT, Shennan A, Hald K, Heikinheimo O, Jacobsson B, Hjartardottir H, Karypidis H, Glavind J. Nordic randomised trial on laparoscopic versus vaginal cerclage (NORACT): trial protocol for an international, multicentre, randomised controlled trial. BMJ Open. 2025 Sep 23;15(9):e107093. doi: 10.1136/bmjopen-2025-107093.
PMID: 40987744DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Niels Uldbjerg, DMSc
Aarhus University Hospital
- PRINCIPAL INVESTIGATOR
Julie Glavind, MD, PhD
Aarhus University Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2023
First Posted
November 8, 2023
Study Start
January 31, 2024
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
March 1, 2028
Last Updated
December 10, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Beginning three months and ending three years after the publication of the last trial results.
- Access Criteria
- Data will be available for any research purpose to all interested parties who have approval from an independent review committee. Interested parties will be able to request the data by contacting the trial sponsor. Authorship of publications emerging from the shared data will follow standard authorship guidelines and will include authors from the NORACT Board depending on the nature of their involvement.
After publication of the trial results, the final dataset will be publicly available in an anonymized form using i.e. Zenodo open data repository (CERN) or another equivalent database.